Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Acute Leukaemia

Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission: risk factors for long-term morbidity and mortality

Bone Marrow Transplantation volume 31, pages 877–887 (2003)Cite this article

Summary:

In this single-centre retrospective study, we analysed risk factors for nonrelapse long-term morbidity and mortality in patients with acute myeloblastic leukaemia (AML) who had undergone allogeneic transplantation. A total of 112 patients with de novo AML in first complete remission (CR1), n=90 or second complete remission (CR2, n=22) who received un-manipulated bone marrow grafts from human leukocyte antigen identical siblings between January 1985 and August 2000 were included. Of these, 97 patients alive and disease-free for at least 100 days after transplant were selected for the purpose of this long-term analysis. The use of an intensified conditioning regimen, Gram-negative bacteriaemia before transplantation, year of transplantation and number of pretransplant chemotherapy courses for patients in CR1 significantly affected the 7-year event-free survival which was 57%. 7-year transplant-related mortality TRM was 22%. Significant predictors for TRM were: bacterial infections before transplantation, major ABO blood group incompatibility, late severe bacterial infections, and chronic (graft-versus-host disease) GvHD. Predictive factors for late severe bacterial infections were infections before transplant, total body irradiation and GvHD. Incidence and risk factors for other late events including, chronic GvHD, late infections, osteonecrosis, cataract, endocrine- cardiac- and lung-complications, cancer and performance status at last follow-up were also studied. The analysis strongly suggests that the combination of pretransplant factors such as chemotherapy and conditioning, and posttransplant factors such as chronic GvHD had a major impact on late nonrelapse morbidity and mortality.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995; 332: 217–223.

    Article  CAS  PubMed  Google Scholar 

  2. Harousseau JL, Cahn JY, Pignon B et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1997; 90: 2978–2986.

    CAS  PubMed  Google Scholar 

  3. Burnett AK, Goldstone AH, Stevens RM et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351: 700–708.

    Article  CAS  PubMed  Google Scholar 

  4. Ravindranath Y, Yeager AM, Chang MN et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1996; 334: 1428–1434.

    Article  CAS  PubMed  Google Scholar 

  5. Amadori S, Testi AM, Arico M et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. J Clin Oncol 1993; 11: 1046–1054.

    Article  CAS  PubMed  Google Scholar 

  6. Woods WG, Neudorf S, Gold S et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's cancer group. Blood 2001; 97: 56–62.

    Article  CAS  PubMed  Google Scholar 

  7. Cassileth PA, Harrington DP, Appelbaum FR et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission [see comments]. N Engl J Med 1998; 339: 1649–1656.

    Article  CAS  PubMed  Google Scholar 

  8. Fenaux P, Chevret S, Guerci A et al. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia 2000; 14: 1371–1377.

    Article  CAS  PubMed  Google Scholar 

  9. Anderlini P, Ghaddar HM, Smith TL et al. Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first. Leukemia 1996; 10: 964–996.

    CAS  PubMed  Google Scholar 

  10. Kantarjian HM, Keating MJ, Walters RS et al. The characteristics and outcome of patients with late relapse acute myelogenous leukemia. J Clin Oncol 1988; 6: 232–238.

    Article  CAS  PubMed  Google Scholar 

  11. Gale RP, Horowitz MM, Weiner RS et al. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant 1995; 16: 203–208.

    CAS  PubMed  Google Scholar 

  12. Creutzig U, Ritter J, Schellong G . Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. Blood 1990; 75: 1932–1940.

    CAS  PubMed  Google Scholar 

  13. Michel G, Leverger G, Leblanc T et al. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Bone Marrow Transplant 1996; 17: 191–196.

    CAS  PubMed  Google Scholar 

  14. Frassoni F, Labopin M, Gluckman E et al. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time—a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT). Bone Marrow Transplant 1996; 17: 13–18.

    CAS  PubMed  Google Scholar 

  15. Bortin MM, Horowitz MM, Gale RP et al. Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s. JAMA 1992; 268: 607–612.

    Article  CAS  PubMed  Google Scholar 

  16. Sullivan KM, Agura E, Anasetti C et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28: 250–259.

    CAS  PubMed  Google Scholar 

  17. Tabbara IA . Allogeneic bone marrow transplantation: acute and late complications. Anticancer Res 1996; 16: 1019–1026.

    CAS  PubMed  Google Scholar 

  18. Deeg HJ . Early and late complications of bone marrow transplantation. Curr Opin Oncol 1990; 2: 297–307.

    Article  CAS  PubMed  Google Scholar 

  19. Socie G, Stone JV, Wingard JR et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999; 341: 14–21.

    Article  CAS  PubMed  Google Scholar 

  20. Castaigne S, Chevret S, Lepage E et al. Prognostic factors of acute non lymphoblastic leukemia in children and adults. Results from two multicentric trials (705 patients). Nouv Rev Fr Hematol 1990; 32: 297–300.

    CAS  PubMed  Google Scholar 

  21. Castaigne S, Archimbaud E, Fenaux P et al. Role of double induction in the treatment of acute myeloblastic leukemia in the adult: intermediate results of protocol LAM90. Nouv Rev Fr Hematol 1994; 36: S139–S140.

    PubMed  Google Scholar 

  22. Michel G, Baruchel A, Tabone MD et al. Induction chemotherapy followed by allogeneic bone marrow transplantation or aggressive consolidation chemotherapy in childhood acute myeloblastic leukemia. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Hematol Cell Ther 1996; 38: 169–176.

    Article  CAS  PubMed  Google Scholar 

  23. Storb R, Deeg HJ, Pepe M et al. Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial [see comments]. Br J Haematol 1989; 72: 567–572.

    Article  CAS  PubMed  Google Scholar 

  24. Storb R, Deeg HJ, Pepe M et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73: 1729–1734.

    CAS  PubMed  Google Scholar 

  25. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204–217.

    Article  CAS  PubMed  Google Scholar 

  26. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.

    Article  CAS  PubMed  Google Scholar 

  27. Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063–4071.

    CAS  PubMed  Google Scholar 

  28. Meyers JD, Flournoy N, Thomas ED . Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153: 478–488.

    Article  CAS  PubMed  Google Scholar 

  29. Clift RA, Buckner CD, Thomas ED et al. The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 1987; 2: 243–258.

    CAS  PubMed  Google Scholar 

  30. Ferrant A, Labopin M, Frassoni F et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood 1997; 90: 2931–2938.

    CAS  PubMed  Google Scholar 

  31. Woods WG, Kobrinsky N, Buckley J et al. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study. J Clin Oncol 1993; 11: 1448–1457.

    Article  CAS  PubMed  Google Scholar 

  32. Keating MJ, Smith TL, Kantarjian H et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 1988; 2: 403–412.

    CAS  PubMed  Google Scholar 

  33. McGlave PB, Haake RJ, Bostrom BC et al. Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission. Blood 1988; 72: 1512–1517.

    CAS  PubMed  Google Scholar 

  34. Keating S, Suciu S, de Witte T et al. Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC- GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups. Bone Marrow Transplant 1996; 17: 993–1001.

    CAS  PubMed  Google Scholar 

  35. Tallman MS, Kopecky KJ, Amos D et al. Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission. J Clin Oncol 1989; 7: 326–337.

    Article  CAS  PubMed  Google Scholar 

  36. Mayer RJ, Davis RB, Schiffer CA et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B [see comments]. N Engl J Med 1994; 331: 896–903.

    Article  CAS  PubMed  Google Scholar 

  37. Tallman MS, Rowlings PA, Milone G et al. Effect of postremission chemotherapy before human leukocyte antigen- identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood 2000; 96: 1254–1258.

    CAS  PubMed  Google Scholar 

  38. Cahn JY, Labopin M, Sierra J et al. No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000; 110: 308–314.

    Article  CAS  PubMed  Google Scholar 

  39. Fopp M, Fey MF, Bacchi M et al. Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1997; 8: 251–257.

    Article  CAS  PubMed  Google Scholar 

  40. Cassileth PA, Lynch E, Hines JD et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992; 79: 1924–1930.

    CAS  PubMed  Google Scholar 

  41. Jourdan E, Maraninchi D, Reiffers J et al. Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia. Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant 1997; 19: 875–881.

    Article  CAS  PubMed  Google Scholar 

  42. Hill GR, Krenger W, Ferrara JL . The role of cytokines in acute graft-versus-host disease. Cytokines Cell Mol Ther 1997; 3: 257–266.

    CAS  PubMed  Google Scholar 

  43. Krenger W, Hill GR, Ferrara JL . Cytokine cascades in acute graft-versus-host disease. Transplantation 1997; 64: 553–558.

    Article  CAS  PubMed  Google Scholar 

  44. Sanders JE . Bone marrow transplantation for pediatric leukemia. Pediatr Ann 1991; 20: 671–676.

    Article  CAS  PubMed  Google Scholar 

  45. Curtis RE, Rowlings PA, Deeg HJ et al. Solid cancers after bone marrow transplantation [see comments]. N Engl J Med 1997; 336: 897–904.

    Article  CAS  PubMed  Google Scholar 

  46. Deeg HJ, Leisenring W, Storb R et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood 1998; 91: 3637–3645.

    CAS  PubMed  Google Scholar 

  47. Bhatia S, Ramsay NK, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633–3639.

    CAS  PubMed  Google Scholar 

  48. Kulkarni S, Powles R, Treleaven J et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 2000; 95: 3683–3686.

    CAS  PubMed  Google Scholar 

  49. Giralt SA, LeMaistre CF, Vriesendorp HM et al. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. J Clin Oncol 1994; 12: 1923–1930.

    Article  CAS  PubMed  Google Scholar 

  50. Yau JC, LeMaistre CF, Andersson BS et al. Allogeneic bone marrow transplantation for hematological malignancies following etoposide, cyclophosphamide, and fractionated total body irradiation. Am J Hematol 1992; 41: 40–44.

    Article  CAS  PubMed  Google Scholar 

  51. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990; 76: 1867–1871.

    CAS  PubMed  Google Scholar 

  52. Bacigalupo A, Van Lint MT, Occhini D et al. ABO compatibility and acute graft-versus-host disease following allogeneic bone marrow transplantation. Transplantation 1988; 45: 1091–1094.

    Article  CAS  PubMed  Google Scholar 

  53. Mehta J, Powles R, Treleaven J et al. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine. Bone Marrow Transplant 1996; 18: 741–746.

    CAS  PubMed  Google Scholar 

  54. Winston DJ, Ho WG, Champlin RE . Current approaches to management of infections in bone marrow transplants. Eur J Cancer Clin Oncol 1989; 25 (Suppl. 2): S25–S35.

    PubMed  Google Scholar 

  55. Wald A, Leisenring W, van Burik JA, Bowden RA . Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation [see comments]. J Infect Dis 1997; 175: 1459–1466.

    Article  CAS  PubMed  Google Scholar 

  56. McWhinney PH, Kibbler CC, Hamon MD et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993; 17: 397–404.

    Article  CAS  PubMed  Google Scholar 

  57. Wingard JR, Beals SU, Santos GW et al. Aspergillus infections in bone marrow transplant recipients. Bone Marrow Transplant 1987; 2: 175–181.

    CAS  PubMed  Google Scholar 

  58. Michel G, Socie G, Gebhard F et al. Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation—a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 1997; 15: 2238–2246.

    Article  CAS  PubMed  Google Scholar 

  59. Sanders JE, Pritchard S, Mahoney P et al. Growth and development following marrow transplantation for leukemia. Blood 1986; 68: 1129–1135.

    CAS  PubMed  Google Scholar 

  60. Cohen A, Duell T, Socie G et al. Nutritional status and growth after bone marrow transplantation (BMT) during childhood: EBMT Late-Effects Working Party retrospective data. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1999; 23: 1043–1047.

    Article  CAS  PubMed  Google Scholar 

  61. Cohen A, Rovelli A, Bakker B et al. Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT. Blood 1999; 93: 4109–4115.

    CAS  PubMed  Google Scholar 

  62. Nguyen Q, Champlin R, Giralt S et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis 1999; 28: 618–623.

    Article  CAS  PubMed  Google Scholar 

  63. Prentice HG, Gluckman E, Powles RL et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994; 343: 749–753.

    Article  CAS  PubMed  Google Scholar 

  64. Prentice HG, Gluckman E, Powles RL et al. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group. Bone Marrow Transplant 1997; 19: 129–133.

    Article  CAS  PubMed  Google Scholar 

  65. Steer CB, Szer J, Sasadeusz J et al. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant 2000; 25: 657–664.

    Article  CAS  PubMed  Google Scholar 

  66. Han CS, Miller W, Haake R, Weisdorf D . Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 1994; 13: 277–283.

    CAS  PubMed  Google Scholar 

  67. Atkinson K, Meyers JD, Storb R et al. Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia. Transplantation 1980; 29: 47–50.

    Article  CAS  PubMed  Google Scholar 

  68. Locksley RM, Flournoy N, Sullivan KM, Meyers JD . Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985; 152: 1172–1181.

    Article  CAS  PubMed  Google Scholar 

  69. Deeg HJ, Storb R, Thomas ED . Bone marrow transplantation: a review of delayed complications. Br J Haematol 1984; 57: 185–208.

    Article  CAS  PubMed  Google Scholar 

  70. Selby PJ, Powles RL, Easton D et al. The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. Br J Cancer 1989; 59: 434–438.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Huma Z, Boulad F, Black P et al. Growth in children after bone marrow transplantation for acute leukemia. Blood 1995; 86: 819–824.

    CAS  PubMed  Google Scholar 

  72. Uderzo C, Biagi E, Rovelli A et al. Bone marrow transplantation for childhood hematological disorders: a global pediatric approach in a twelve year single center experience. Pediatr Med Chir 2000; 21: 157–163.

    CAS  PubMed  Google Scholar 

  73. Leahey AM, Teunissen H, Friedman DL et al. Late effects of chemotherapy compared to bone marrow transplantation in the treatment of pediatric acute myeloid leukemia and myelodysplasia. Med Pediatr Oncol 1999; 32: 163–169.

    Article  CAS  PubMed  Google Scholar 

  74. Socie G . Is syndrome ‘X’ another late complication of bone-marrow transplantation?. Lancet 2000; 356: 957–958.

    Article  CAS  PubMed  Google Scholar 

  75. Socie G, Curtis RE, Deeg HJ et al. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol 2000; 18: 348–357.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Haematology Department, Bone Marrow Transplant Unit, Hospital Saint Louis, Paris, France

    M Robin, P Guardiola, H Esperou, P Ribaud, A Devergie, E Gluckman & G Socié

  2. Haematology Department, Adult Haematology Unit, Bone marrow transplant unit Hospital Saint Louis, Paris, France

    H Dombret

  3. Haematology Department, Pediatric Heamatology unit, Hospital Saint Louis, Paris, France

    A Baruchel

Authors
  1. M Robin
    View author publications

    Search author on:PubMed Google Scholar

  2. P Guardiola
    View author publications

    Search author on:PubMed Google Scholar

  3. H Dombret
    View author publications

    Search author on:PubMed Google Scholar

  4. A Baruchel
    View author publications

    Search author on:PubMed Google Scholar

  5. H Esperou
    View author publications

    Search author on:PubMed Google Scholar

  6. P Ribaud
    View author publications

    Search author on:PubMed Google Scholar

  7. A Devergie
    View author publications

    Search author on:PubMed Google Scholar

  8. E Gluckman
    View author publications

    Search author on:PubMed Google Scholar

  9. G Socié
    View author publications

    Search author on:PubMed Google Scholar

Additional information

The first two authors contributed equally to this study and both should be considered as first author

Rights and permissions

Reprints and permissions

About this article

Cite this article

Robin, M., Guardiola, P., Dombret, H. et al. Allogeneic bone marrow transplantation for acute myeloblastic leukaemia in remission: risk factors for long-term morbidity and mortality. Bone Marrow Transplant 31, 877–887 (2003). https://doi.org/10.1038/sj.bmt.1704027

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704027

Keywords

This article is cited by

Search

Advanced search

Quick links